Johnson & Johnson (JNJ) announced the submission of a supplemental Biologics License Application to the FDA seeking approval of a ...
Leerink Partners analyst David Risinger has maintained their bullish stance on JNJ stock, giving a Buy rating on November 14.Don't Miss our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback